PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml
Authors:
- E.JEffrey MetterEME.JEffrey Metter
- Patricia LandisPLPatricia Landis
- H.BAllentine CarterHCH.BAllentine Carter
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of AgingUrology, 2001
- Prostate-specific antigen levels in young white and black men 20 to 45 years oldUrology, 2000
- Comparative Efficiency of Prostate-Specific Antigen Screening Strategies for Prostate Cancer DetectionJAMA, 2000
- PREDICTORS OF FIRST REPEAT BIOPSY CANCER DETECTION WITH SUSPECTED LOCAL STAGE PROSTATE CANCERJournal of Urology, 2000
- PROSTATE SPECIFIC ANTIGEN VARIATION IN PATIENTS WITHOUT CLINICALLY EVIDENT PROSTATE CANCERJournal of Urology, 1999
- PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mLUrology, 1999
- Prostate Cancer Detection in Men With Serum PSA Concentrations of 2.6 to 4.0 ng/mL and Benign Prostate ExaminationJAMA, 1997
- Pitfalls in Interpreting Prostate Specific Antigen VelocityJournal of Urology, 1996
- Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocityUrology, 1995
- Serum Prostate-Specific Antigen in a Community-Based Population of Healthy MenJAMA, 1993